Elimination: The elimination rate of intravenous administered fluticasone propionate is linear over the 250-1000 mcg dose range and are characterised by a high plasma clearance (CL=/min). Peak plasma concentrations are reduced by approximately 98% within 3-4 hours and only low plasma concentrations were associated with the terminal half-life. The renal clearance of fluticasone propionate is negligible (<%) and less than 5% as the carboxylic acid metabolite. The major route of elimination is the excretion of fluticasone propionate and its metabolites in the bile.
Beclometasone dipropionate was first patented in 1962 and used medically in 1972.  It was approved for medical use in the United States in 1976.  It is on the World Health Organization's List of Essential Medicines , the most effective and safe medicines needed in a health system .  The wholesale price in the developing world for an inhaler containing 200 doses of medication is about USD as of 2014.  In the United States it costs between 50 and 100 USD for a typical month supply of the inhaled form. 
The main pharmacological effects of digoxin are on the heart . Extracardiac effects are responsible for some of the therapeutic and many of the adverse effects (see above). It exerts a mechanical effect as it increases myocardial contractility; however, the duration of the contractile response is only slightly increased. High ventricular rate leads to insufficient diastolic filling time. By slowing down the conduction in the AV node and increasing its refractory period, digoxin can reduce the ventricular rate. The arrhythmia itself is not affected, but the pumping function of the heart improves, owing to improved filling.